Biotech entity
pharma is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention GenBioPro, the most common co-covered peer. Each story carries 6 original sources on average, compared with 2.5 for the broader beat in this window.
Last mentioned: Mar 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 2 tracked stories. Of the tracked stories, 2 of 2 also mention GenBioPro, the most common co-covered peer. Each story carries 6 original sources on average, compared with 2.5 for the broader beat in this window. At 7, the average consequence score sits above the same-window beat average of 5.9. Danco Laboratories appears in 2 tracked Biotech stories from March 24, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 20 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Danco Laboratories. Shared-story counts are live from our verified record — not editorial picks.
Data Stabilization
National reports confirm abortion rates remain steady despite ongoing state restrictions.
SCOTUS Ruling
Supreme Court preserves access to mifepristone by ruling plaintiffs lacked standing in FDA challenge.
Retail Launch
CVS and Walgreens begin dispensing abortion pills in select states.
FDA Rule Change
FDA officially allows retail pharmacies to dispense mifepristone with a prescription.
Dobbs Decision
U.S. Supreme Court overturns Roe v. Wade, allowing state-level bans.
Telehealth Shift
FDA permanently removes the requirement that mifepristone be dispensed in person.
Label Update
FDA expands usage to 70 days gestation and reduces required office visits.
FDA Approval
FDA approves Mifeprex (mifepristone) for medical termination of pregnancy.
Medication abortion has surged to account for the majority of pregnancy terminations in the U.S., driven by telehealth expansion and mail-order access. This shift has catalyzed a sophisticated legal and legislative counter-offensive aimed at the FDA's regulatory authority and the distribution of pharmaceutical products.
National data reveals that abortion rates in the United States have remained steady or increased despite a wave of state-level bans following the Dobbs decision. This trend is driven by a significant shift toward medication abortion and the rapid expansion of telehealth services protected by state shield laws.
Danco Laboratories is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
